| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/14/2005 | US20050153904 Dialysis method |
| 07/14/2005 | US20050153902 Inhibitors of integrin avb6 |
| 07/14/2005 | US20050153900 Novel inhibitors of hepatitis C virus NS3/NS4a serine protease |
| 07/14/2005 | US20050153890 Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| 07/14/2005 | US20050153885 Treatment of conditions through modulation of the autonomic nervous system |
| 07/14/2005 | US20050153873 Frequency assisted transdermal agent delivery method and system |
| 07/14/2005 | US20050153871 Administering N-hydroxy-N-(4-butyl-2-methylphenyl)-formamidine (HET0016) to increase or prevent a decrease in cerebral blood flow |
| 07/14/2005 | US20050153870 Medicinal composition for diagnosis, prevention, or therapy of multiple risk factor syndrome |
| 07/14/2005 | US20050153389 Method for the production of bioactive substances from the novel actinomycete taxon MAR2 ("Marinophilus") |
| 07/14/2005 | US20050153366 Protein-protein interaction antagonist screening libraries based upon 1,4-disubstituted naphthalenes and related scaffolds |
| 07/14/2005 | US20050153337 iRNA conjugates |
| 07/14/2005 | US20050153335 Expression vector comprising nucleotide sequences coding membrane protein for use in identifying modulator for prevention and treatmment of cell proliferative, inflammatory and nervous system disorders |
| 07/14/2005 | US20050153315 Nucleotide sequences coding polypeptide comprising methylarginase activities for use in identifying modulator for prevention and treatment of ischemia-reperfusion injuries, cancer, hypotension, multi-organ failure, arthritis, skin, inflammatory, cardiac and/or migraine disorders |
| 07/14/2005 | US20050153000 Herbal extract and compound lupinoside and its analogues as anti-diabetic type II drugs from plant pueraria tuberosa |
| 07/14/2005 | US20050152999 supercritically extracting an herb to obtain an oil extract and a residue;extracting the residue in a water/alcohol liquid mixture to obtain a post-supercritical hydroalcoholic extract; evaporating the water/alcohol liquid to form a powdered extract; mixing the powdered extract with the oil extract. |
| 07/14/2005 | US20050152998 Peppermint isopropyl alcohol |
| 07/14/2005 | US20050152995 comprising contacting tissues with agents that prevents glial scar formation and optionally agent that increases bcl-2 protein levels in neurons |
| 07/14/2005 | US20050152991 peroxyoctanoic acid, octanoic acid, carrier, and solubilizer, oxidizers; can be readily made, and/or can exhibit reduced odor; microbiocide |
| 07/14/2005 | US20050152989 Method for treating irritable bowel syndrome |
| 07/14/2005 | US20050152983 micronized; directly compressible rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid; stable and bioavailable |
| 07/14/2005 | US20050152982 acceptable dissolution enhancer having a low concentration of carboxylic acid and ester substituents; relatively large amount of the drug can be delivered at a controlled rate over a relatively long period of time; reduces side-effect of diarrhea |
| 07/14/2005 | US20050152980 Pharmeutical microparticles |
| 07/14/2005 | US20050152979 comprising: a hydrophobic biologically active molecule or active agent; a polymeric carrier that renders the active agent soluble in water, and a reconstitution enhancer or enhancing agent; lyophilized |
| 07/14/2005 | US20050152978 Capsule, tablet with enteric, protective coatings; bioavailability |
| 07/14/2005 | US20050152975 Pharmaceutical composition |
| 07/14/2005 | US20050152974 once daily "pulsed" dosage form; first subunit comprises atomoxetine and a first release-retarding material and the second subunit comprises atomoxetine and a second release-retarding material |
| 07/14/2005 | US20050152972 disintegrates and dissolves slowly in the mouth to sooth the irritated area, and which is non-irritating to sensitive areas of the mouth |
| 07/14/2005 | US20050152968 Microemulsions for pharmaceutical compositions |
| 07/14/2005 | US20050152967 Comprises expectorant for immediate release and decongestant for extended release that provide for symptomatic relief of cough associated with respiratory tract conditions |
| 07/14/2005 | US20050152962 Composition for treatment of inflammatory disorders |
| 07/14/2005 | US20050152959 Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell |
| 07/14/2005 | US20050152958 Ketoprofen patch delivery system |
| 07/14/2005 | US20050152957 Compositions and delivery systems for administration of a local anesthetic agent |
| 07/14/2005 | US20050152956 Therapy for sexual disorders |
| 07/14/2005 | US20050152951 Liquid, eye-instillable preparations comprising sodium hyaluronate |
| 07/14/2005 | US20050152930 Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use |
| 07/14/2005 | US20050152926 For immunization and/or diagnosis; eg pneumonia, cardiovascular diseases, atherosclerosis, bronchitis |
| 07/14/2005 | US20050152921 Modified CpG oligodeoxynucleotide with improved immunoregulatory function |
| 07/14/2005 | US20050152913 Process for preapring maytansinol |
| 07/14/2005 | US20050152909 Prostate stem cell antigen (PSCA) tumor antigen for use in diagnosis, prevention and treatment of prostate cancers |
| 07/14/2005 | US20050152905 by concurrent administration of prostaglandin inhibitors, modulator of neurotransmitters, interleukin inhibitors and tumor necrosis factor -lpha (TNF-alpha) inhibitors |
| 07/14/2005 | US20050152897 Methods for inducing T cell tolerance to a tissue or organ graft |
| 07/14/2005 | US20050152893 Methods and materials for the inhibition of transplant rejection |
| 07/14/2005 | US20050152885 Reduce development of colorectal cancer by supplying enterically aminoglycoside antibiotic to intestines |
| 07/14/2005 | US20050152874 Unblocking immunization at a regional lymph node by: promoting differentiation and maturation of immature dendritic cells in a regional lymph node and; allowing presentation by resulting mature dendritic cells of antigen to T-cells |
| 07/14/2005 | US20050152870 Pharmaceutical composition which improves in vivo gene transfer |
| 07/14/2005 | US20050152865 Ceramide emulsions |
| 07/14/2005 | US20050152859 Inhibitors of melanocyte tyrosinase as topical skin lighteners |
| 07/14/2005 | US20050152856 0.5-7% by weight of D,L- alpha -lipoic acid, 0.05-0.5% by weight of coenzyme Q-10 and 0.01-3% by weight of acetyl-L-carnitine hydrochloride; treatment of visible sun injuries caused by processes involving the action of free radicals |
| 07/14/2005 | US20050152852 cocoa inhibits the growth of the periodontal disease bacteria such as Porphyromonas gingivalis and has excellent antibacterial activity against periodontal disease bacteria |
| 07/14/2005 | US20050152850 Methods and compositions for facilitating metabolic control |
| 07/14/2005 | US20050152847 Novel formulation |
| 07/14/2005 | US20050152846 Hydrofluoroalkane (HFA) propellant and co-solvents; inhalants; storage stability; deep lung penetration |
| 07/14/2005 | US20050152845 Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form |
| 07/14/2005 | US20050152843 Heat pressing a mixture of an active ingredient with abuse potential, a high strength polymer, and a wax into a controlled release dosage form; cannot be dispersed or even dissolved in such a manner that it may safely be administered parenterally, in particular intravenously |
| 07/14/2005 | US20050150489 Dispensing medicaments based on rates of medicament action |
| 07/14/2005 | DE202005006527U1 Dry galenic combination preparation for improving condition of joints, comprising rapid release glucosamine, chondroitin and copper and selenium salts and retarded release vitamins and minerals |
| 07/14/2005 | DE202004003241U1 Solubilized, high bioavailability vitamin product, comprising vitamin A (or its ester) and excess emulsifier, especially polysorbate 80 |
| 07/14/2005 | DE10361067A1 Medikamentöse Lipolyse von Fettansammlungen Drug lipolysis of fat accumulation |
| 07/14/2005 | DE10360151A1 New 3-oxo-1-propenyl azo compounds useful as 5-HT receptor antagonists e.g. for treating psychoses, neurological disorders, amyotrophic lateral sclerosis and eating disorders |
| 07/14/2005 | DE10359960A1 New glucopyranosyloxy-pyrazole derivatives are sodium dependent glucose cotransporter inhibitors used for treating and preventing metabolic disorders, particularly diabetes |
| 07/14/2005 | DE10358534A1 Adhäsionshemmung von Mikroorganismen durch nichtionische Tenside Adhesion inhibition of microorganisms by nonionic surfactants |
| 07/14/2005 | DE10358004A1 Ketolactam-Verbindungen und ihre Verwendung -Keto lactam compounds and their use |
| 07/14/2005 | DE10357044A1 Verfahren zur Dotierung von organischen Halbleitern mit Chinondiiminderivaten Method for doping of organic semiconductors with Chinondiiminderivaten |
| 07/14/2005 | DE10035620B4 Verwendung von Taurin als neuroprotektives Agens in der Ophthalmologie Use of taurine as a neuroprotective agent in ophthalmology |
| 07/14/2005 | CA2801848A1 Methods for controlling sr protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control sr protein activity |
| 07/14/2005 | CA2676121A1 Processes for preparing different forms of (s)-(+)-clopidogrel bisulfate |
| 07/14/2005 | CA2592504A1 Classification of cancer |
| 07/14/2005 | CA2552311A1 Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity |
| 07/14/2005 | CA2552305A1 Use of macrolides for treating or preventing airflow obstruction |
| 07/14/2005 | CA2552228A1 Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders |
| 07/14/2005 | CA2552095A1 Novel crystalline forms of temozolomide |
| 07/14/2005 | CA2551920A1 Methods for inducing differentiation of undifferentiated mammalian cells into osteoblasts |
| 07/14/2005 | CA2551806A1 Methods of preparing olanzapine |
| 07/14/2005 | CA2551696A1 Immunopotentiator and method of enhancing immunoactivity using the same |
| 07/14/2005 | CA2551657A1 Composition comprising an aqueous extract of red vine leaves and a antithrombotic agent for the treatment of chronic venous insufficiences |
| 07/14/2005 | CA2551637A1 Melatonin combination therapy for improving sleep quality |
| 07/14/2005 | CA2551611A1 Thiazole derivatives for treating or preventing parkinson's disease |
| 07/14/2005 | CA2551604A1 Amidopyrazole derivative |
| 07/14/2005 | CA2551602A1 Methods for controlling sr protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control sr protein activity |
| 07/14/2005 | CA2551580A1 Composition comprising an aqueous extract of red vine leaves and a blood circulation-improving agent for the treatment of chronic venous insufficiences |
| 07/14/2005 | CA2551567A1 Propofol analogs, process for their preparation, and methods of use |
| 07/14/2005 | CA2551553A1 Modulation of 5-ht2 receptors as a treatment for cardiovascular diseases |
| 07/14/2005 | CA2551552A1 5-ht2 receptors modulators, their pharmaceuticals compositions and their use for the treatment of cardiovascular and muscle diseases |
| 07/14/2005 | CA2551474A1 Medical lipolysis of fat accumulations |
| 07/14/2005 | CA2551227A1 Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies |
| 07/14/2005 | CA2551117A1 Substituted melatonin derivatives, process for their preparation, and methods of use |
| 07/14/2005 | CA2551100A1 Compositions and methods for combined therapy of disease |
| 07/14/2005 | CA2551050A1 Crystal form of quinoline compound and process for its production |
| 07/14/2005 | CA2550983A1 Enhanced absorption of modified release dosage forms |
| 07/14/2005 | CA2550948A1 Crf receptor antagonists and methods relating thereto |
| 07/14/2005 | CA2550943A1 Methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid |
| 07/14/2005 | CA2550866A1 Methods and dosage forms for increasing solubility of drug compositions for controlled delivery |
| 07/14/2005 | CA2550735A1 Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| 07/14/2005 | CA2550730A1 Method and compositions for identifying anti-hiv therapeutic compounds |
| 07/14/2005 | CA2550729A1 Rifamycin analogs and uses thereof |
| 07/14/2005 | CA2550727A1 Treatment of coronary or peripheral ischemia |
| 07/14/2005 | CA2550689A1 Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof |
| 07/14/2005 | CA2550686A1 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 07/14/2005 | CA2550679A1 Substituted n-aryl amidines as selective d1 dopamine receptor antagonists for the treatment of obesity and cns disorders |